Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2011 Filed Mar 11, 2011 16:07 UTC |
Silva Paul MVP & Corp Controller
|
SaleCommon Stock | 1,525 | $45.73 | $69,738.25 |
DisclosureSEC source: 0001209191-11-017266 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · VP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $45.73 (range $45.22 to $45.99). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2011 Filed Mar 4, 2011 20:29 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
Exercise / conversionStock Option · Derivative | 9,531 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-11-015485 · doc4.xml · derivative · entry 4 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,062 Underlying: Common Stock · 9,531 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008. Read SEC document |
| March 03, 2011 Filed Mar 4, 2011 20:29 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
SaleCommon Stock | 9,531 | $49.50 | $471,784.50 |
DisclosureSEC source: 0001209191-11-015485 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,154 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 03, 2011 Filed Mar 4, 2011 20:29 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
Exercise / conversionCommon Stock | 9,531 | $18.93 | $180,421.83 |
DisclosureSEC source: 0001209191-11-015485 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2011 Filed Mar 4, 2011 20:35 UTC |
Kelly LisaSVP, Human Resources
|
Exercise / conversionStock Option · Derivative | 13,343 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-11-015489 · doc4.xml · derivative · entry 4 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,157 Underlying: Common Stock · 13,343 shares Expires 2017-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/12/2007. Read SEC document |
| March 03, 2011 Filed Mar 4, 2011 20:35 UTC |
Kelly LisaSVP, Human Resources
|
SaleCommon Stock | 13,343 | $50.00 | $667,150.00 |
DisclosureSEC source: 0001209191-11-015489 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,242 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 03, 2011 Filed Mar 4, 2011 20:35 UTC |
Kelly LisaSVP, Human Resources
|
Exercise / conversionCommon Stock | 13,343 | $28.84 | $384,812.12 |
DisclosureSEC source: 0001209191-11-015489 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2011 Filed Mar 3, 2011 20:28 UTC |
Kelly LisaSVP, Human Resources
|
Exercise / conversionStock Option · Derivative | 11,438 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-11-014962 · doc4.xml · derivative · entry 4 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,625 Underlying: Common Stock · 11,438 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008. Read SEC document |
| March 02, 2011 Filed Mar 3, 2011 20:28 UTC |
Kelly LisaSVP, Human Resources
|
SaleCommon Stock | 11,438 | $47.50 | $543,305.00 |
DisclosureSEC source: 0001209191-11-014962 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,242 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 02, 2011 Filed Mar 3, 2011 20:28 UTC |
Kelly LisaSVP, Human Resources
|
Exercise / conversionCommon Stock | 11,438 | $18.93 | $216,521.34 |
DisclosureSEC source: 0001209191-11-014962 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 21:32 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
Exercise / conversionStock Option · Derivative | 11,915 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000875320-11-000019 · edgar.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,593 Underlying: Common Stock · 11,915 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 21:32 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
SaleCommon Stock | 3,972 | $45.00 | $178,740.00 |
DisclosureSEC source: 0000875320-11-000019 · edgar.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,154 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 21:32 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
SaleCommon Stock | 11,915 | $46.00 | $548,090.00 |
DisclosureSEC source: 0000875320-11-000019 · edgar.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,126 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 21:32 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
Exercise / conversionCommon Stock | 11,915 | $18.93 | $225,550.95 |
DisclosureSEC source: 0000875320-11-000019 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 21:36 UTC |
Kelly LisaSVP, Human Resources
|
Exercise / conversionStock Option · Derivative | 11,437 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000875320-11-000020 · edgar.xml · derivative · entry 4 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,063 Underlying: Common Stock · 11,437 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 21:36 UTC |
Kelly LisaSVP, Human Resources
|
SaleCommon Stock | 11,437 | $45.00 | $514,665.00 |
DisclosureSEC source: 0000875320-11-000020 · edgar.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,242 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 21:36 UTC |
Kelly LisaSVP, Human Resources
|
Exercise / conversionCommon Stock | 11,437 | $18.93 | $216,502.41 |
DisclosureSEC source: 0000875320-11-000020 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2011 Filed Feb 24, 2011 21:33 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
Exercise / conversionStock Option · Derivative | 23,828 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000875320-11-000018 · edgar.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,446 Underlying: Common Stock · 23,828 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008. Read SEC document |
| February 23, 2011 Filed Feb 24, 2011 21:33 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
SaleCommon Stock | 11,914 | $44.00 | $524,216.00 |
DisclosureSEC source: 0000875320-11-000018 · edgar.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,126 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 23, 2011 Filed Feb 24, 2011 21:33 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
SaleCommon Stock | 11,914 | $43.60 | $519,450.40 |
DisclosureSEC source: 0000875320-11-000018 · edgar.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,040 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 23, 2011 Filed Feb 24, 2011 21:33 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
Exercise / conversionCommon Stock | 23,828 | $18.93 | $451,064.04 |
DisclosureSEC source: 0000875320-11-000018 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2011 Filed Feb 9, 2011 20:09 UTC |
BOGER JOSHUA SDirector
|
GiftCommon Stock | 39,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-11-000017 · edgar.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,395 F1 · shares: Common stock given to family members. Read SEC document |
| February 06, 2011 Filed Feb 7, 2012 21:29 UTC |
Emmens MatthewExecutive Chairman
|
SaleCommon Stock | 40,600 | $38.08 | $1,546,048.00 |
DisclosureSEC source: 0001209191-12-008147 · doc4.xml · nonDerivative · entry 3 Emmens Matthew · CIK 0001298332 · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,601 F1 · kind: Transaction made pursuant to Mr. Emmens' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Emmens undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $38.08 (range $37.70 to $38.33). Read SEC document |
| February 06, 2011 Filed Feb 7, 2012 21:29 UTC |
Emmens MatthewExecutive Chairman
|
SaleCommon Stock | 12,900 | $37.11 | $478,719.00 |
DisclosureSEC source: 0001209191-12-008147 · doc4.xml · nonDerivative · entry 2 Emmens Matthew · CIK 0001298332 · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,201 F1 · kind: Transaction made pursuant to Mr. Emmens' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Emmens undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $37.11 (range $36.68 to $37.67). Read SEC document |
| February 06, 2011 Filed Feb 7, 2012 21:29 UTC |
Emmens MatthewExecutive Chairman
|
SaleCommon Stock | 2,500 | $36.39 | $90,975.00 |
DisclosureSEC source: 0001209191-12-008147 · doc4.xml · nonDerivative · entry 1 Emmens Matthew · CIK 0001298332 · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,101 F1 · kind: Transaction made pursuant to Mr. Emmens' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $36.39 (range $35.64 to $36.61). F3 · price: Mr. Emmens undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:52 UTC |
Emmens MatthewDirector · President & CEO
|
GrantStock Option · Derivative | 236,000 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000008 · edgar.xml · derivative · entry 2 Emmens Matthew · CIK 0001298332 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,000 Underlying: Common Stock · 236,000 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:52 UTC |
Emmens MatthewDirector · President & CEO
|
GrantCommon Stock | 47,201 | $0.01 | $472.01 |
DisclosureSEC source: 0000875320-11-000008 · edgar.xml · nonDerivative · entry 1 Emmens Matthew · CIK 0001298332 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,406 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:53 UTC |
BOGER KENNETH SSVP & General Counsel
|
GrantStock Options · Derivative | 45,750 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000009 · edgar.xml · derivative · entry 3 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:53 UTC |
BOGER KENNETH SSVP & General Counsel
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-11-000009 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,752 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:54 UTC |
SMITH IAN FEVP & CFO
|
GrantStock Option · Derivative | 54,375 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000010 · edgar.xml · derivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,375 Underlying: Common Stock · 54,375 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:54 UTC |
SMITH IAN FEVP & CFO
|
GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0000875320-11-000010 · edgar.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,877 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:56 UTC |
MUELLER PETERDirector · EVP, Global R&D, CSO
|
GrantStock Option · Derivative | 72,500 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000011 · edgar.xml · derivative · entry 3 MUELLER PETER · CIK 0001256126 · Director · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:56 UTC |
MUELLER PETERDirector · EVP, Global R&D, CSO
|
GrantCommon Stock | 14,501 | $0.01 | $145.01 |
DisclosureSEC source: 0000875320-11-000011 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · Director · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,735 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:57 UTC |
Wysenski NancyEVP & Chief Commercial Officer
|
GrantStock Option · Derivative | 54,375 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000012 · edgar.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,375 Underlying: Common Stock · 54,375 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:57 UTC |
Wysenski NancyEVP & Chief Commercial Officer
|
GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0000875320-11-000012 · edgar.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,084 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:57 UTC |
Kelly LisaSVP, Human Resources
|
GrantStock Option · Derivative | 45,750 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000013 · edgar.xml · derivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:57 UTC |
Kelly LisaSVP, Human Resources
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-11-000013 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,242 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:58 UTC |
Silva Paul MV.P. and Corporate Controller
|
GrantStock Option · Derivative | 15,000 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000014 · edgar.xml · derivative · entry 3 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:58 UTC |
Silva Paul MV.P. and Corporate Controller
|
GrantCommon Stock | 3,000 | $0.01 | $30.00 |
DisclosureSEC source: 0000875320-11-000014 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 20:00 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
GrantStock Option · Derivative | 45,750 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000015 · edgar.xml · derivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 20:00 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-11-000015 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,126 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 20:01 UTC |
Stamoulis ChristianaSVP, Corp Strategy & Bus Devlp
|
GrantStock Option · Derivative | 58,250 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000016 · edgar.xml · derivative · entry 3 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,250 Underlying: Common Stock · 58,250 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 20:01 UTC |
Stamoulis ChristianaSVP, Corp Strategy & Bus Devlp
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-11-000016 · edgar.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,813 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| January 25, 2011 Filed Jan 26, 2011 20:25 UTC |
SMITH IAN FEVP & CFO
|
SaleCommon Stock | 6,042 | $40.71 | $245,969.82 |
DisclosureSEC source: 0000875320-11-000007 · edgar.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,793 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $40.71 (range $40.66 to $40.72). F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 25, 2011 Filed Jan 26, 2011 20:23 UTC |
Kelly LisaSVP, Human Resources
|
SaleCommon Stock | 471 | $40.78 | $19,207.38 |
DisclosureSEC source: 0000875320-11-000006 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,076 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan established under Rule 10b5-1. Read SEC document |
| January 21, 2011 Filed Jan 25, 2011 18:09 UTC |
SMITH IAN FEVP & CFO
|
SaleCommon Stock | 6,042 | $39.93 | $241,257.06 |
DisclosureSEC source: 0000875320-11-000003 · edgar.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,835 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $39.93 (range $39.75 to $40.04). F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 21, 2011 Filed Jan 25, 2011 18:10 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
SaleCommon Stock | 2,128 | $39.92 | $84,949.76 |
DisclosureSEC source: 0000875320-11-000004 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,960 F1 · kind: Transaction made pursuant to Mr. Sachdev's comany approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $39.92 (range $39.77 to $40.02). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 21, 2011 Filed Jan 25, 2011 18:11 UTC |
Kelly LisaSVP, Human Resources
|
SaleCommon Stock | 1,709 | $39.93 | $68,240.37 |
DisclosureSEC source: 0000875320-11-000005 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,547 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $39.93 (range $39.81 to 40.02). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 18, 2011 Filed Jan 20, 2011 17:33 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
Exercise / conversionStock Option · Derivative | 11,914 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000875320-11-000002 · edgar.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,336 Underlying: Common Stock · 11,914 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008. Read SEC document |
| January 18, 2011 Filed Jan 20, 2011 17:33 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
SaleCommon Stock | 3,750 | $39.50 | $148,125.00 |
DisclosureSEC source: 0000875320-11-000002 · edgar.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,088 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.